Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Ocoxin used alongside chemotherapy may improve patients' tolerance to treatment and their quality of life without significant safety concerns, although further research is needed.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.